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Introduction {#s1}
============

Over the past decade, the incidence of diabetes has increased dramatically. The WHO estimates mortality due to diabetes to increase by 50% in the next 10 y, making it a major cause of death by 2030 and placing a substantial economic burden on the health care system globally ([@c62]; [@c7]). Therefore, understanding the underlying factors of this global epidemic is critical. It has been well established that factors such as food intake and sedentary lifestyle significantly influence the incidence of diabetes. Although these are important factors, changes in our lifestyle have also increased our exposure to a variety of synthetic chemicals that are linked to various diseases such as diabetes and obesity in experimental models and human epidemiological studies ([@c5]; [@c40]; [@c52]; [@c67]).

Bisphenol A (BPA) is one such synthetic chemical to which we are ubiquitously exposed through food, drink, and skin contact ([@c89]). Detectable amounts of BPA are found in urine samples of populations from around the world ([@c66]; [@c89]; [@c109]). Exposure to BPA has been associated with prediabetes and type 2 diabetes in human cross sectional ([@c1]; [@c2]; [@c75]; [@c80]) and longitudinal studies ([@c90]). Such associations have been further confirmed using animal models of exposure during adulthood ([@c4]; [@c11]).

The pancreas undergoes substantial remodeling during late gestation and early neonatal life. This involves formation of new $\beta\,\text{cells}$ by differentiation of precursor cells during late gestation ([@c32]) followed by substantial remodeling, including high rates of replication and cell death in the neonatal period ([@c27]; [@c79], [@c78]; [@c93]). The $\beta - \text{cell}$ replication rate gradually declines ([@c27]; [@c93]), and post-weaning $\beta - \text{cell}$ turnover is regulated by $\beta - \text{cell}$ death and very slow rates of replication ([@c15]; [@c79]). An exposure to synthetic chemicals such as BPA during this vulnerable period is even more concerning because of the potential to not only alter normal fetal development, but also to impact later life health and disease. Furthermore, the fetus is particularly vulnerable to the effects of BPA because the degradation pathways are immature, leading to accumulation and high levels of BPA ([@c94]; [@c107]). Consistent with this finding, our previous studies and studies by others have shown that perinatal exposure to BPA leads to metabolic defects in offspring ([@c6]; [@c8]; [@c59]; [@c98]; [@c101]) and in subsequent generation offspring ([@c55]; [@c92]). We recently demonstrated that maternal exposure via maternal transmission to relevant human exposure levels of BPA, $10\;\mu g/{kg}/d$ (LowerB) or $10\;{mg}/{kg}/d$ (UpperB) prior to conception and through lactation is associated with higher body fat, impaired glucose tolerance, and reduced glucose-stimulated insulin secretion (GSIS) across two generations in adult male mice offspring ([@c92]). Despite our expanding knowledge on the association of BPA with increased risk of diabetes, the mechanisms underlying this link remain to be elucidated.

In the current study, we tested the hypothesis that early developmental exposure to BPA alters key aspects of $\beta - \text{cell}$ function leading to impaired insulin secretion in the offspring and that these changes would persist across two generations.

Materials and Methods {#s2}
=====================

Experimental Paradigm {#s2.1}
---------------------

The animal work was conducted with the approval of the University of Pennsylvania Institutional Animal Care and Use Committee. All animals were treated humanely and with regard for alleviation of suffering. The animals used in this study were generated using the same procedure as described previously ([@c92]). (See Figure S1 for the experimental design.) C57BL/6 virgin female mice (F0) were randomly assigned to the following three diets from 2 wk prior to mating until weaning: $10\;\mu g/{kg}/d$ (LowerB), $10\;{mg}/{kg}/d$ (UpperB) BPA, and 7% corn oil (Control). These doses were selected based on our previous study ([@c91]), where we reported that the levels of unconjugated BPA in serum from pregnant mice were representative of human exposure levels ([@c91]). The offspring after weaning, and the subsequent generations, were maintained on the control diet. All terminal tests were performed in 16- to 21-wk-old first- (F1) and second-generation (F2) adult offspring, other than cell viability assays that were performed in 8- to 10-wk-old offspring. The experiments were blinded, where possible (e.g., immunofluorescence staining and Luminex assay). To account for robustness of the studied outcomes and cohort consistency in our paradigm, the end points measured were from animals generated across multiple cohorts studied in two different animal care facilities, with a control group included in all cohorts (see Figure S2). For most assessments, $n = 5 - 6$ litters per group were used other than for extensive cytokine assays, RNA seq, islet perifusion ramps, and islet cytosolic calcium determination where mice from $n = 3–4$ litters per group were used. Metabolic studies including GSIS and $\alpha - \text{ketoisocaproate}$ ramp studies were performed in both male and female offspring. However, because no metabolic phenotype was observed in female offspring across two generations, all mechanistic studies were performed on males only. Females were only additionally assessed for transcriptomic differences via RNA seq to determine if there were additional pathways we did not anticipate that might be disrupted in the islet.

Islet Isolation {#s2.2}
---------------

F1 and F2 adult mice pancreata were perfused with Hanks' balanced salt solution (Life Technologies) supplemented with 2.5% bovine serum albumin (BSA) (wt/vol; Sigma), $0.35\; g/L$ $\text{NaHCO}_{3}$ (Sigma), and $2\;{mg}/{mL}$ Collagenase P (Roche); excised; and incubated at 37°C for 10--15 min. After digestion, islets were washed and then purified using a Histopaque 10771 and Histopaque 11191 (Sigma) gradient. To provide sufficient starting material for Oroboros, RNA and DNA extraction, islets had to be pooled from 2--3 male mice (either male or female for RNA) from within the same litter. This helped minimize the within-litter variability, which is not uncommon in endocrine-disruptor models. For remaining evaluations, one mouse per litter was randomly selected as a litter representative. More than one islet-specific end point was determined for each litter, where possible (see Figure S2). A combination of studied outcomes from pooled as well as from an individual animal from each litter helped in assessing both nonrandom and stochastic biological changes.

Insulin Measurement and Islet Perifusion Study {#s2.3}
----------------------------------------------

Isolation of pancreatic islets, perifusion, and insulin assays were performed as previously described ([@c53]). In brief, islets were isolated by collagenase digestion and cultured with $10\,\text{mM}$ glucose in RPMI 1640 medium (Sigma) for 2 d. Islets were perifused with a Krebs-Ringer bicarbonate buffer containing 0.25% BSA at a flow rate of $1\;{mL}/\text{min}$. Ramps at increments of $0.5\,\text{mM}/\text{min}$ for glucose, and $0.3\,\text{mM}/\text{min}$ for $\alpha - \text{ketoisocaproate}$ were performed. Thirty millimolar potassium chloride was used to determine maximum insulin release. Insulin was measured in the perfusates following the ramp studies, as well as in the lysates from freshly isolated islets by homogeneous time*-*resolved fluorescence technology (Cisbio Kit).

Islet Mitochondrial Function by High-Resolution Respirometry {#s2.4}
------------------------------------------------------------

A high-resolution respirometry was performed in $\sim 800$ overnight-cultured intact islets using $\text{Oxygraph} - 2K$ (Oroboros Instruments, Innsbruck, Austria). The intact islets were diluted with RPMI and $1–1.5\,\text{million}$ cells/chamber were added to each chamber of the $\text{Oxygraph} - 2K$ in $2\;{mL}$ volume per chamber. For each experiment, two Oroboros machines were used at a time, and in each machine islets from one of the BPA-exposed groups and Control were run in parallel. The use of chambers for a particular treatment and control was switched between the experiments to avoid any bias due to chamber differences. The experiment was performed at 37°C with constant magnetic stirring set at 750 rpm. After the addition of intact islets into the oxygraph chambers, the basal respiration referred to as the ROUTINE state was measured when a stable oxygen flux was reached. Following this step, inhibitors for the different mitochondrial respiratory complexes were added and oxygen consumption of mitochondria was measured according to established protocol published previously ([@c110]). The inhibitors were added in the following order: oligomycin ($3\;\mu M$) (Sigma), to inhibit complex V (to assess nonmitochondrial respiratory capacity or proton LEAK rate), carbonyl cyanide-*p*-trifluoro-methoxyphenylhydrazone (*FCCP*) (Sigma) uncoupler with stepwise titration in $0.5 - \text{to}\, 1.5 - \mu M$ increments \[to assess maximal electron transport system respiratory capacity rate (ETS)\]. Rotenone (Sigma) was added in a $0.5 - \mu M$ final concentration to inhibit complex I, and antimycin A (Sigma) in a $2.5 - \mu M$ final concentration was added last to inhibit complex III. Data was analyzed using DatLab4 and DatLab6 (Oroboros, Austria) software, and normalized to the total DNA concentration.

Islet Cytosolic Calcium Levels {#s2.5}
------------------------------

In isolated islets, cytosolic calcium $\left\lbrack {Ca}^{2 +} \right\rbrack_{i}$ responses were measured by dual-wavelength fluorescence microscopy using Fura-2AM (Life Technologies) as a calcium indicator, and calcium dynamics were measured with the Zeiss AxioVision system (Carl Zeiss Microscopy, Thornwood, NY) ([@c54]).

Histology {#s2.6}
---------

Pancreata were excised, and fixed in 10% formalin (pH 7.0) for 48 h at room temperature, and embedded in paraffin (Tissue-Tek, 4,583). Six sections of $5\;\mu m$ thickness, $100\;\mu m$ apart were selected for immunohistochemical (IHC) and immunofluorescence (IF) staining per animal. Prior to any antigen-specific staining, subsets of sections from each animal were H & E stained, and assessed by an independent, blinded pathologist for section quality (see Figure S3). All slides were pretreated in an antigen retriever with either $0.01\; M$ citrate buffer pH 7.6 (Vector Labs), or pH9 Retrieval Solution (DAKO), and blocked using 2% fetal bovine serum.

For immunohistochemical staining, slides were incubated in primary F4/80 antibody (Invitrogen) 1:50 overnight at 4°C, or CD3 antibody (Santa Cruz) 1:250 for 2 h at room temperature. Secondary anti-rat IgG (Vector Lab) and anti-goat IgG (Vector Lab) antibodies were used in a 1:200 dilution for 30 min at room temperature.

For immunofluorescence staining, slides were incubated with antibodies against insulin (Abcam) 1:50 for 16 h at 4°C, glucagon (Biogenix) 1:50 for 1 h at room temperature, and somatostatin (Biorad) 1:50 for 1 h at room temperature. Secondary antibodies Alexa Fluor® 594 anti-guinea pig (Invitrogen), Alexa Fluor® 647 anti-rabbit (Invitrogen), and Alexa Fluor® 488 anti-rat (Invitrogen) 1:200 were applied for 1 h at room temperature in the dark. The nuclei were stained using DAPI (Sigma). To quantify staining, slides were digitally scanned at $20 \times$ magnification on an Aperio Scanscope CS-O (brightfield) and Scanscope IF (fluorescent) (Leica Biosystems). Nonfluorescent staining was analyzed by ImageScope v12.2.2.5015 (Leica Biosystems) using Aperio-Color Deconvolution v9.1 algorithm. The area of CD3 and F4/80 staining was calculated within islets, pancreatic lymph nodes, and non-islet tissue by multiplying percent positive staining with total stained area and the product was normalized to total analysis area. Fluorescent staining was analyzed by HALO v2.0.1018 (Indica Lab) using Indica Labs Area Quantification FL v1.0 algorithm. Islets were identified as insulin surrounded by glucagon and somatostatin staining. Beta-, alpha-, and delta-cell mass was calculated by multiplying the average insulin, glucagon, and somatostatin stained area, respectively, within each islet relative to the total area scanned with the pancreatic weight and then corrected for body weight measured at tissue harvest.

Cytokine Measurement {#s2.7}
--------------------

The cytokine and chemokine panels were measured in pancreatic lysates by mouse Cytokine/Chemokine Luminex 25plex Assay with a detection limit of $3.2\,\text{pg}/{mL}$ to $10,000\,\text{pg}/{mL}$ (EMD Millipore), as described previously ([@c37]). Interleukin-6 (IL6) and monocyte chemoattractant protein-1 (MCP1) levels were confirmed using mouse ELISA kits (Thermo Fisher). Cytokine levels were normalized to total protein concentration measured by BCA (bicinchoninic acid) assay (Pierce).

RNA Sequencing {#s2.8}
--------------

Total RNA was extracted from pooled islets using the Trizol and Qiagen RNeasy mini kit following the manufacturer's instructions. RNA integrity was determined using Agilent RNA 6000 Nano Kit and samples with an RNA integrity number of $> 7$ were used to make RNA libraries. TruSeq Illumina RNA libraries were sequenced using the high-throughput whole transcriptome next generation sequencing to generate 60--80 million reads per sample. Fastq data was processed with HTSeq-count v0.6.1, and aligned using STAR v2.4.0 software. The edgeR v3.12.1 was used to find differentially expressed genes via $\log_{2}\text{FC}$ and false discovery rate values. Functional analyses were conducted using Ingenuity Pathway Analysis (Ingenuity Systems; <http://www.ingenuity.com>).

Islet mRNA Expression Analysis {#s2.9}
------------------------------

RNA extracted from pooled islets with an RNA integrity number of $> 7$ were used for gene expression analysis. Using Biorad iScript kit, cDNA was subsequently generated. Real-time polymerase chain reaction (PCR) was performed using TaqMan Gene expression assay in Applied Biosystems 7900HT Fast Real-Time PCR System. F1 data was normalized to *Rpl19* and *Beta actin*, and F2 data was normalized to *Rpl19* and *Cyclophilin A (Ppia).* The primers and probes are listed in Table S1.

Islet Protein Expression Analysis {#s2.10}
---------------------------------

The levels of estrogen receptor alpha (ESR1) and uncoupling protein 2 (UCP2) proteins were measured in lysates by using mouse ESR1 (Aviva Systems Biology), and mouse UCP2-Ab (MyBioSource) ELISA kits, following the manufacturer's instructions. Target protein levels were normalized to total protein concentration measured by BCA assay (Pierce).

Islet DNA Methylation Analysis {#s2.11}
------------------------------

DNA was extracted from pooled islets using the QIAmp DNA Mini Kit (Qiagen), and $1\;\mu g$ of DNA was bisulfite treated using the EpiTect Bisulfite Kit (Qiagen) following the manufacturer's protocol. Pyrosequencing was conducted to measure the methylation status of the promoter region of the *Igf2* DMR1 (chr7: 149,851,180--149,851,655; NCBI37/MM9) and *H19/Igf2* ICR (chr7: 149,767,599--149,767,819; NCBI37/MM9), and exon A and exon C of the *Esr1* gene as described previously by Susiarjo et al. ([@c91]) and Kundakovic et al. ([@c50]), respectively. Briefly, $50\,\text{ng}$ of purified bisulfite-treated DNA was amplified using a PyroMark PCR kit (Qiagen) and primers specific for the *Igf2* DMR1, *H19/Igf2* ICR, and exon A and exon C of the *Esr1*gene (see Table S2). Ten microliters of the biotinylated PCR product was used for each sequencing assay and sequenced using a PyroMark Q96MD (Qiagen) pyrosequencer and PyroMark Gold 96 reagents kit (Qiagen) and specific pyrosequencing primers (see Table S2). Percent methylation levels of CpG sites were quantified using Qiagen's Pyro Q-CpG software.

Islet Viability Assays {#s2.12}
----------------------

Lysates from freshly isolated islets from 8- to 10-wk-old F1 and F2 mice were assessed for apoptosis using the caspase 3 activity fluorometric assay (Abcam), BCL2 levels using the mouse BCL2 ELISA kit (LS Bio), and phospho-AKT (pSer473) and total AKT levels using the AKT (pSer473) + total AKT ELISA kit (Abcam) following the manufacturer's instructions.

Statistical Analysis {#s2.13}
--------------------

For comparison between LowerB with Control, and UpperB with Control, we used Dunnett's test, which accounts for multiple testing. For pyrosequencing data, using Dunnett's test, we statistically analyzed methylation levels at individual CpG sites as well as mean methylation across all CpG sites for our two BPA treatment groups relative to Control. In addition, we performed multivariate analyses of variance followed by repeated measures response design to determine *a*) methylation levels differ between the groups, *b*) methylation levels differ between CpG sites, and *c*) differences in methylation levels across CpG sites interact with study groups. Nonparametric data were log-transformed to approximate a standard distribution, where required. All values are presented as $\text{mean} \pm \text{SEM}$. A $p - \text{value}\,\text{of} < 0.05$ was considered significant. All data were analyzed using JMP and Prism analysis software.

Results {#s3}
=======

Dose- and Sex-Specific Effects of Maternal BPA Exposure on Islet Mitochondrial Function in F1 and F2 Adult Offspring {#s3.1}
--------------------------------------------------------------------------------------------------------------------

Using our mouse model of BPA exposure, we previously observed impaired GSIS in the F1 and F2 generation adult male offspring of mothers (F0) exposed to $10\;\mu g/{kg}/d$ (LowerB) or $10\;{mg}/{kg}/d$ (UpperB) relative to Controls (7% corn oil diet) ([@c92]). Nutrient-induced insulin secretion requires ATP production from mitochondria ([@c9]; [@c68]). Mitochondrial dysfunction has been associated with $\beta - \text{cell}$ failure in islets of intrauterine growth-restricted rats ([@c82]). To assess whether impaired GSIS in F1 and F2 adult male offspring is due to altered mitochondrial driven insulin secretion, we measured insulin secretion in response to $\alpha - \text{ketoisocaproate}$, a substrate metabolized in mitochondria. Surprisingly, $\alpha - \text{ketoisocaproate}$--stimulated insulin secretion in the islets of F1 and F2 LowerB males was comparable to levels in Controls. However, it trended to be reduced in F1 and F2 UpperB males relative to Controls ([Figure 1](#f1){ref-type="fig"}), thus reflecting an abnormal mitochondrial phenotype in islets of UpperB males. We saw no differences in glucose or $\alpha - \text{ketoisocaproate}$--stimulated insulin secretion in LowerB or UpperB F1 or F2 females compared with Control females ([Figure 2](#f2){ref-type="fig"}). Therefore, all further studies were conducted exclusively in adult male offspring.

![Mitochondrial driven insulin secretion in islets of F1 and F2 adult male offspring: (*A, C*) F1 and (*B, D*) F2 adult male offspring. The maximal KIC-stimulated insulin release was calculated as the insulin area under the curve for $15\,\text{mM}$ KIC. Data are individual litter data (one animal per litter), presented as $\text{mean} + \text{SEM}$, and analyzed using Dunnett's test. *p*-Values are relative to Control. Note: KCL, potassium chloride; KIC, $\alpha - \text{ketoisocaproate}$.](EHP1674_f1){#f1}

![Glucose-stimulated and mitochondrial associated insulin secretion in islets of F1 and F2 adult female offspring: (*A--B*, *E--F*) F1, and (*C--D*, *G--H*) F2 adult female offspring. The maximal glucose- and KIC-stimulated insulin release was calculated as the insulin area under the curve for $25\,\text{mM}$ glucose or $15\,\text{mM}$ KIC, respectively. Data are individual litter data (one animal per litter), presented as $\text{mean} + \text{SEM}$, and analyzed using Dunnett's test. $p - \text{Values}$ are relative to Control. Note: KCL, potassium chloride; KIC, $\alpha - \text{ketoisocaproate}$.](EHP1674_f2){#f2}

To determine whether the phenotype in males was associated with mitochondrial dysfunction, we performed high-resolution respirometry to assess oxygen consumption in intact islet mitochondria using Oroboros. Consistent with the above results, we did not see any difference in oxygen consumption in the intact islets of F1 and F2 LowerB males, but did observe reduced basal and maximal oxygen consumption in the intact islets of F1 and F2 UpperB males relative to Controls ([Figure 3](#f3){ref-type="fig"}). These results are consistent with abnormal mitochondrial function in the islets of the UpperB males, and the reduction in GSIS in F1 and F2 LowerB males may be due to a factor other than a mitochondrial defect.

![Basal and maximal mitochondrial oxygen consumption in islets of F1 and F2 adult male offspring: (*A--B*) F1, and (*C--D*) F2 adult male offspring. Data are individual litter data (islets pooled from 2--3 males from the same litter) with mean superimposed. Data were analyzed using Dunnett's test. *p*-values are relative to Control. Oxygen flow per cell at: ROUTINE, i.e., basal state of cell respiration; electron transport system \[ETS; uncoupled; carbonyl cyanide-*p*-trifluoro-methoxyphenylhydrazone (FCCP)\]; and residual oxygen consumption (rox; rotenone, antimycin A).](EHP1674_f3){#f3}

Others have shown that BPA exposure alters expression of key mitochondrial genes such as oxoglutarate dehydrogenase (*Ogdh*) and uncoupling protein 2 (*Ucp2*) in rodent islets ([@c101]; [@c85]). Because we observed mitochondrial dysfunction in the current study, we sought to determine whether these previously demonstrated mitochondrial targets of BPA are affected. OGDH is the rate-limiting enzyme in the tricarboxylic acid (TCA) cycle, which plays a key role in mitochondrial function. UCP2 is a member of the mitochondrial carrier family whose loss of function mutation can cause hyperinsulinism, whereas its overexpression is associated with the efflux of TCA cycle intermediates out of the mitochondria, thereby reducing acetyl-CoA--oxidizing substrates in the mitochondria ([@c31]; [@c100]). *Ogdh* expression was only mildly increased in LowerB F2 males compared with Controls ([Table 1](#t1){ref-type="table"}). In contrast, *Ucp2* mRNA levels were significantly increased in LowerB and UpperB F1 and F2 males compared with Controls ([Table 1](#t1){ref-type="table"}). The changes in mitochondrial gene expression are consistent with UpperB F1 and F2 mitochondrial impairment, although these changes did not translate to statistically significant differences in protein expression levels. F1 and F2 UpperB males (F1 $4.0 \times 10^{- 4} \pm 1.0 \times 10^{- 5}\text{ng}/\mu g$, $p = 0.43$; F2 $6.3 \times 10^{- 4} \pm 1.7 \times 10^{- 5}\text{ng}/\mu g$, $p = 0.74$; $n = 5$) and LowerB males (F1 $4.3 \times 10^{- 4} \pm 1.0 \times 10^{- 5}\text{ng}/\mu g$, $p = 0.31$; F2 $6.1 \times 10^{- 4} \pm 1.7 \times 10^{- 5}\text{ng}/\mu g$, $p = 0.80$; $n = 5$) had increased UCP2 protein levels relative to Controls (F1 $2.3 \times 10^{- 4} \pm 1.0 \times 10^{- 5}\text{ng}/\mu g$; F2 $4.7 \times 10^{- 4} \pm 1.7 \times 10^{- 5}\text{ng}/\mu g$; $n = 5$); however, these findings were not statistically significant.

###### 

mRNA Levels in islets of F1 and F2 Lower BPA and Upper BPA male mice.

Table 1 lists genes in the first column; the corresponding fold change in mRNA expression levels of these genes for Lower BPA and Upper BPA relative to Control are listed in the second and third columns, respectively.

  Gene                    Lower BPA (95% CI)      Upper BPA (95% CI)
  ----------------------- ----------------------- -----------------------
  *Igf2*                                           
   F1                     1.67 (1.20, 2.31)^\*^   2.19 (1.71, 2.79)^\*^
   F2                     1.48 (1.03, 2.30)^\*^   1.23 (1.13, 1.34)^\*^
  *Ucp2*                                           
   F1                     1.51 (1.03, 2.21)^\*^   2.54 (1.52, 3.24)^\*^
   F2                     2.05 (1.78, 2.36)^\*^   1.74 (1.05, 3.08)^\*^
  *Ogdh*                                           
   F1                     0.97 (0.72, 1.29)       1.40 (0.96, 2.03)
   F2                     1.20 (1.18, 1.22)^\*^   1.32 (0.97, 1.80)
  *Esr1*                                           
   F1                     0.70 (0.53, 0.93)^\*^   0.88 (0.82, 0.94)^\*^
   F2                     0.38 (0.18, 0.84)^\*^   0.48 (0.24, 0.97)^\*^
  *Pdx1*                                           
   F1                     1.32 (0.82, 2.11)       1.72 (1.11, 2.64)^\*^
   F2                     1.31 (0.86, 2.00)       1.21 (0.48, 3.03)
  *Igf1*                                           
   F1                     1.05 (0.95, 1.15)       1.55 (1.10, 2.19)^\*^
   F2                     1.08 (0.94, 1.25)       1.23 (1.13, 1.34)^\*^
  $\mathit{Hnf1}\alpha$                            
   F1                     1.06 (0.89, 1.27)       1.43 (1.30, 1.59)^\*^
   F2                     1.00 (0.85, 1.17)       1.21 (0.94, 1.57)
  *Kcnj11*                                         
   F1                     1.54 (0.70, 3.41)       0.94 (0.45, 1.99)
   F2                     1.56 (0.92, 2.64)       1.06 (0.36, 3.12)
  *Abcc8*                                          
   F1                     1.48 (0.75, 2.92)       0.99 (0.55, 1.78)
   F2                     1.94 (1.48, 2.54)^\*^   1.46 (0.63, 3.37)
  *Snap25*                                         
   F1                     1.02 (0.43, 2.38)       0.71 (0.30, 1.65)
   F2                     1.46 (0.66, 3.26)       1.17 (0.38, 3.61)

Note: Data were normalized to *Rpl19* and *Beta actin* or *Ppia* mRNA levels and expressed as fold change relative to Controls (where Control is set at 1.0) with 95% confidence intervals (CI) in islets of F1 and F2 Lower BPA ($10\;\mu g/{kg}/d$) and Upper BPA ($10\;{mg}/{kg}/d$) male mice. $n = 5$ litters per group; islets pooled from 2--3 male mice per litter. \*$p < 0.05$ vs. Controls.

Dose-Specific Effects of Maternal BPA Exposure on $\beta - \textit{\textbf{cell}}$ Mass in F1 and F2 Adult Male Offspring {#s3.2}
-------------------------------------------------------------------------------------------------------------------------

An alternative hypothesis for reduced insulin secretion is that BPA exposure is associated with a reduction in the number of insulin-secreting cells. To determine whether reduced GSIS in BPA-exposed F1 and F2 male offspring is linked to reduced $\beta - \text{cell}$ mass, we stained pancreatic sections with anti-insulin, glucagon and somatostatin antibodies to quantify $\beta - \text{cell}$, alpha-, and delta-cell mass, respectively. F1 and F2 LowerB males had reduced $\beta - \text{cell}$ mass adjusted for body weight relative to Controls ([Figure 4](#f4){ref-type="fig"}). F1 and F2 UpperB and Control males had comparable $\beta - \text{cell}$ mass. Alpha-cell mass was similar among the F1 males, but F2 LowerB males had a modest increase in alpha-cell mass compared with Controls (see Figure S4). F1 and F2 LowerB and UpperB had comparable delta mass as Controls (see Figure S4). Thus, LowerB exposure specifically reduced $\beta - \text{cell}$ mass across two generations. We also measured pancreatic insulin content in F1 and F2 males. UpperB had similar (F1 $0.005 \pm 0.001\,\text{ng}/\mu g$, $p = 0.97$; F2 $0.002 \pm 0.001\,\text{ng}/\mu g$, $p = 0.93$; $n = 6$), whereas LowerB tended to have reduced insulin content (F1 $0.002 \pm 0.001\,\text{ng}/\mu g$, $p = 0.10$; F2 $0.001 \pm 0.0006\,\text{ng}/\mu g$, $p = 0.08$; $n = 6$) relative to Controls (F1 $0.004 \pm 0.001\,\text{ng}/\mu g$; F2 $0.003 \pm 0.001\,\text{ng}/\mu g$; $n = 6$).

![Beta cell mass of F1 and F2 adult male offspring. Representative photomicrographs of pancreatic immunofluorescent staining in (*A--C*) F1 and (*D--F*) F2 Control, LowerB, UpperB male mice. All images have insulin (red), glucagon (green), somatostatin (yellow), and DAPI (blue). Image magnified $20 \times$. Data are individual litter data (one animal per litter) with mean superimposed from (*G*) F1 and (*H*) F2 males, analyzed by Dunnett's test. *p*-Values are relative to Control.](EHP1674_f4){#f4}

We then examined possible mechanisms underlying the reduction in $\beta - \text{cell}$ mass. Caspase 3 activity, a marker of cell death, was significantly increased in islets of F1 and F2 LowerB males but not in islets from UpperB males ([Figure 5](#f5){ref-type="fig"}). BCL2, an anti-apoptotic protein, did not differ in F1or F2 LowerB compared with Controls, but levels were increased in F1 UpperB males relative to Controls ($p = 0.05$; [Figure 5](#f5){ref-type="fig"}). These changes were associated with increased AKT phosphorylation in F1 and F2 UpperB males relative to Controls. F1 and F2 LowerB males had similar AKT phosphorylation as Controls ([Figure 5](#f5){ref-type="fig"}). AKT phosphorylation mediates the cell survival response by inhibiting programed cell death ([@c72]; [@c103]). Thus, the UpperB group had increased AKT phosphorylation and no difference in islet cell death and $\beta - \text{cell}$ mass, whereas the LowerB group has increased islet cell death and decreased $\beta - \text{cell}$ mass across two generations.

![Cell viability in islets of (*A--C*) F1 and (*D--F*) F2 male offspring. Data are individual litter data (one animal per litter) with mean superimposed. Each parameter is normalized to total protein concentration. Data were analyzed using Dunnett's test performed on log-transformed data, where required (BCL2). Note: RFU: relative fluorescence unit. *p*-Values are relative to Control.](EHP1674_f5){#f5}

Effects of Maternal BPA Exposure on Cytokine/Chemokine Levels/Expression in Pancreata of F1 and F2 Adult Male Offspring {#s3.3}
-----------------------------------------------------------------------------------------------------------------------

Several studies indicate that immune cells such as macrophages, dendritic cells, and lymphocytes are present in islets and may play an important role in normal islet development ([@c23]; [@c29]; [@c39], [@c38]). In fact, immune cell defects are linked to abnormal pancreatic development and glucose homeostasis observed in athymic BALB/c nude mice ([@c108]). To explore whether $\beta - \text{cell}$--specific effects of BPA are associated with a perturbed immune response, we assessed the cytokine/chemokine profile in pancreatic lysates of F1 and F2 mice via a Luminex assay. Because different immune cell types produce and respond to different cytokines/chemokines, we have provided a list of these cell types in [Table 2](#t2){ref-type="table"}; see also Tables S3 and S4. In F1 and F2 BPA-exposed versus Control mice levels of the $T_{h}2$ cytokine IL4 was reduced, but IL5 was elevated, and pro-inflammatory cytokines IL6 and MCP1 were also elevated ([Table 2](#t2){ref-type="table"}). Compared with Controls, F1 UpperB males also had increased levels of G-CSF (granulocyte colony stimulating factor) and IL9 (see Table S3). IL17 was increased in F2 LowerB and UpperB males compared with Controls ([Table 2](#t2){ref-type="table"}). The levels of other cytokines measured were comparable among the three groups (see Tables S3 and S4). We validated the changes in levels of key cytokines via ELISA and saw a similar trend of increased cytokine levels of IL6 as well as significantly increased MCP1 levels in F1 and F2 LowerB and UpperB males relative to Controls ([Figure 6](#f6){ref-type="fig"}). This indicated that both doses of BPA increased levels of pro-inflammatory cytokines in islets.

![IL6, MCP1 levels in (*A--B*) F1 and (*C--D*) F2 adult male offspring. Note: IL6, interleukin 6; MCPm: monocyte chemoattractant protein-1. Cytokine levels for each sample were normalized to total protein concentration. Data are individual litter data (one animal per litter) with mean superimposed. Data were analyzed by Dunnett's test performed on log-transformed data, where required (F1 IL6, MCP1; F2 IL6). *p*-Values are relative to Control.](EHP1674_f6){#f6}

###### 

Cytokine/chemokine levels on a LUMINEX assay in pancreatic lysates of F1 and F2 adult male offspring.

Table 2 lists cytokine/chemokine, inflammatory action, production source, and target cell/action in the first, second, third, and fourth columns, respectively. The values of Control, Lower BPA, and Upper BPA, all measured in picograms per microgram, and the p-values for Lower and Upper BPA in the F1 offspring and F2 offspring are listed in the other columns separately. P-Values are relative to Control.

  Cytokine/Chemokine   Inflammatory action   Produced by                                                                                       Target cell/action                                                                                      F1 Offspring          F2 Offspring                                                                                                                           
  -------------------- --------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- --------------------- --------------------- ---------------------- ------ ------ ---------------------- ---------------------- ---------------------- ------ ------
  IL4                  pro/anti              Macrophages, eosinophills, basophills                                                             Macrophages, T cells, $\left. T_{h}0\rightarrow T_{h}2 \right.$                                         $3E - 4 \pm 6E - 5$   $2E - 4 \pm 7E - 5$   $3E - 4 \pm 7E - 5$    0.60   0.75   $3E - 5 \pm 5E - 5$    $1E - 4 \pm 5E - 5$    $2E - 4 \pm 5E - 5$    0.23   0.04
  IL5                  pro/anti              $T_{h}2$ cells, mast Cells                                                                        B-cell growth, $\uparrow$ eosinophills                                                                  $4E - 4 \pm 3E - 5$   $3E - 4 \pm 3E - 5$   $7E - 4 \pm 4E - 5$    0.08   0.01   $2E - 4 \pm 4E - 4$    $4E - 4 \pm 4E - 4$    $13E - 4 \pm 4E - 4$   0.43   0.09
  IL6                  pro/anti              T-cells, macrophages                                                                              $\uparrow$ B-cells, naïve T cells $\rightarrow$$T_{h}17$~,~$\left. \downarrow T_{\text{reg}} \right.$   $6E - 4 \pm 5E - 4$   $7E - 4 \pm 5E - 4$   $22E - 4 \pm 5E - 4$   0.89   0.08   $3E - 4 \pm 6E - 4$    $12E - 4 \pm 6E - 4$   $19E - 4 \pm 5E - 4$   0.15   0.04
  IL17                 pro                   $T_{h}$ cells                                                                                     Recruits macrophages and neutrophils                                                                    $2E - 4 \pm 7E - 5$   $4E - 4 \pm 8E - 5$   $4E - 4 \pm 8E - 5$    0.20   0.33   $1E - 4 \pm 9E - 5$    $2E - 4 \pm 9E - 5$    $4E - 4 \pm 8E - 5$    0.14   0.03
  MCP1                 pro                   Chemoattractant produced by injured tissue, or infection                                          $\uparrow$ Macrophages, memory T cells, dendritic cells, basophils                                      $2E - 3 \pm 4E - 4$   $3E - 3 \pm 5E - 4$   $4E - 3 \pm 5E - 4$    0.18   0.02   $2E - 3 \pm 21E - 4$   $7E - 3 \pm 21E - 4$   $8E - 3 \pm 17E - 4$   0.27   0.09
  $\text{TNF}\alpha$   pro                   Macrophages $\text{CD}4^{+}$, natural killer and mast cells                                       Macrophages, IL1- and IL6-producing cells                                                               $4E - 4 \pm 9E - 5$   $5E - 4 \pm 1E - 4$   $5E - 4 \pm 1E - 4$    0.59   0.53   $2E - 4 \pm 2E - 4$    $3E - 4 \pm 2E - 4$    $4E - 4 \pm 1E - 4$    0.62   0.28
  $\text{IFN}\gamma$   pro                   Natural killer cells, natural killer T-cells, macrophages, $\text{CD}4^{+}$, ${\text{CD}8}^{+}$   Macrophages, $\uparrow$ MHCII                                                                           $2E - 3 \pm 1E - 3$   $4E - 3 \pm 1E - 3$   $4E - 3 \pm 1E - 3$    0.45   0.59   $2E - 3 \pm 6E - 3$    $2E - 3 \pm 6E - 3$    $9E - 3 \pm 5E - 3$    0.99   0.85

Note: Data are normalized to total protein concentration as pg of cytokine or chemokine per $\mu g$ of total protein, and presented as $\text{mean} + \text{SEM}$. Decimal places are represented by E notation, where E represents base 10, followed by the power of 10 (example, $E - 3 = 10^{- 3}$, $E - 4 = 10^{- 4}$, $E - 5 = 10^{- 5}$). Information in columns 2, 3, and 4 is derived from [@c18]; [@c21]; [@c46]; [@c49]; [@c97]. Control, 7% corn oil diet; LowerB, Lower BPA ($10\;\mu g/{kg}/d$); UpperB, Upper BPA ($10\;{mg}/{kg}/d$). $n = 3$ to $4\,\text{litters}$ per group. *p*-Values are from Dunnett's test performed on log-transformed data, where required (F1 IL5, IL6, MCP1, and $\text{IFN}\gamma$; F2 IL4, IL5 IL6, IL17, $\text{TNF}\alpha$, and $\text{IFN}\gamma$).

To verify the increased inflammatory phenotype in the pancreas of F1 and F2 BPA-exposed male mice, we immunostained pancreatic sections with CD3, a marker for T lymphocytes, and with F4/80, a marker for macrophages. We consistently observed increased immunostaining of CD3 and F4/80 in the islets of BPA-exposed F1 and F2 male mice compared with Controls ([Figure 7](#f7){ref-type="fig"}; [Table 3](#t3){ref-type="table"}). Thus, lower- and upper-dose BPA exposure increased islet inflammation across two generations in males. Taken together these findings indicate the recruitment of macrophages and $T_{h}1$ cells and, possibly, the recruitment of neutrophils and activation of eosinophils in the pancreas.

![Representative photomicrographs of pancreatic immunohistochemical staining in F1 and F2 adult male offspring: (*A--H*) F1 and (*I--P*) F2 Control, LowerB, UpperB mice, and Positive Ctrl (internal Control---lymph node). Image magnified $20 \times$. Note: CD3, cluster of differentiation 3 (marker for T lymphocytes); F4/80, marker for macrophages. F1, $n = 6$ litters per group (one animal per litter); F2, $n = 5$ litters Control and UpperB, $n = 4$ litters LowerB (one animal per litter).](EHP1674_f7){#f7}

###### 

Quantification of CD3 and F4/80 staining area in pancreatic sections of F1 and F2 adult male offspring.

Table 3 lists pancreatic sections in the first columns; the corresponding values of control, Lower BPA, and Upper BPA, all measured in millimeter squared per millimeter squared, and the p-values for Lower BPA versus Control and Upper BPA versus Control are listed in the other columns.

  Staining area                                                                                               Control (${mm}^{2}{/{mm}}^{2}$)   LowerB (${mm}^{2}{/{mm}}^{2}$)   UpperB (${mm}^{2}{/{mm}}^{2}$)   LowerB vs. Control (*p*-value)   UpperB vs Control (*p*-value)
  ----------------------------------------------------------------------------------------------------------- --------------------------------- -------------------------------- -------------------------------- -------------------------------- -------------------------------
  Area of percent positive CD3 staining in islets/total analysis area                                                                                                                                                                               
   F1                                                                                                         $14.88 \pm 5.57$                  $29.33 \pm 5.57$                 $35.46 \pm 5.57$                 0.04                             0.02
   F2                                                                                                         $5.02 \pm 2.89$                   $5.90 \pm 3.23$                  $12.21 \pm 2.89$                 0.51                             0.06
  Area of percent positive CD3 staining in pancreas excluding islets and   lymph nodes/total analysis area                                                                                                                                          
   F1                                                                                                         $20.14 \pm 3.43$                  $24.67 \pm 3.43$                 $32.52 \pm 3.43$                 0.42                             0.04
   F2                                                                                                         $2.28 \pm 1.10$                   $6.40 \pm 1.23$                  $4.69 \pm 1.10$                  0.04                             0.18
  Area of percent positive CD3 staining in pancreatic lymph nodes/total   analysis area                                                                                                                                                             
   F1                                                                                                         $23.81 \pm 6.16$                  $42.85 \pm 6.16$                 $44.98 \pm 6.16$                 0.08                             0.05
   F2                                                                                                         $17.99 \pm 6.19$                  $23.37 \pm 6.92$                 $15.47 \pm 6.19$                 0.78                             0.84
  Area of percent positive F4/80 staining in islets/total analysis area                                                                                                                                                                             
   F1                                                                                                         $1.91 \pm 1.01$                   $4.49 \pm 1.01$                  $5.94 \pm 1.01$                  0.12                             0.02
   F2                                                                                                         $3.52 \pm 1.10$                   $6.62 \pm 1.23$                  $7.66 \pm 1.10$                  0.15                             0.04
  Area of percent positive F4/80 staining in pancreas excluding islets and  lymph nodes/total analysis area                                                                                                                                         
   F1                                                                                                         $2.67 \pm 1.62$                   $7.51 \pm 1.62$                  $10.48 \pm 1.62$                 0.09                             0.01
   F2                                                                                                         $7.99 \pm 1.74$                   $12.87 \pm 1.95$                 $15.22 \pm 1.74$                 0.10                             0.03
  Area of percent positive F4/80 staining in pancreatic lymph nodes/total   analysis area                                                                                                                                                           
   F1                                                                                                         $7.74 \pm 3.34$                   $11.81 \pm 3.34$                 $17.46 \pm 3.34$                 0.60                             0.10
   F2                                                                                                         $14.45 \pm 4.17$                  $12.23 \pm 4.66$                 $11.21 \pm 4.17$                 0.94                             0.81

Note: Data are normalized to total analysis area and presented as $\text{mean} \pm \text{SEM}$. Control, 7% corn oil diet; LowerB, Lower BPA ($10\;\mu g/{kg}/d$); UpperB, Upper BPA ($10\;{mg}/{kg}/d$). $n = 4 - 6$ litters per group (one animal per litter). *p*-Values are from Dunnett's test performed on log-transformed data, where required (F1 CD3 islets, F1 CD3 excluding islets and lymph nodes, F2 CD3 islets, F2 F4/80 lymph nodes).

Effects of Maternal BPA Exposure on Estrogen Receptor Alpha Gene Expression in Islets of F1 and F2 Adult Male Offspring {#s3.4}
-----------------------------------------------------------------------------------------------------------------------

The endocrine-disrupting actions of BPA are mediated by both estrogen receptor dependent and independent pathways ([@c105]). Estrogen receptors (ESR1, or *Esr1*) are critically important to $\beta - \text{cell}$ function and development ([@c96]; [@c106]) and have anti-inflammatory effects in other organs ([@c63]). We observed a significant reduction in mRNA expression of *Esr1* in F1 and F2 LowerB and UpperB males compared with Controls ([Table 1](#t1){ref-type="table"}). The *Esr1* mRNA changes in the LowerB group correlated with its protein expression, such that F1 and F2 LowerB males (F1 $0.0002 \pm 0.001\,\text{ng}/\mu g$, $p = 0.09$; F2 $0.0001 \pm 0.0003\,\text{ng}/\mu g$, $p = 0.09$; $n = 5$) trended toward reduced ESR1 protein levels relative to Controls (F1 $0.0010 \pm 0.001\,\text{ng}/\mu g$; F2 $0.0011 \pm 0.0003\,\text{ng}/\mu g$; $n = 5$); however, F1 and F2 UpperB males (F1 $0.0028 \pm 0.001\,\text{ng}/\mu g$, $p = 0.45$; F2 $0.0006 \pm 0.0003\,\text{ng}/\mu g$, $p = 0.48$; $n = 5$) had ESR1 protein levels that were similar to those of Controls. BPA also acts via the estrogen receptor beta (ESR2, or *Esr2*) and alters stimulus-secretion coupling through its effects on $K_{\text{ATP}}$ channels and increasing glucose-stimulated $\left\lbrack {Ca}^{2 +} \right\rbrack_{i}$ levels ([@c87]; [@c86]). We did not observe any difference in either mRNA levels of *Esr2*, $K_{\text{ATP}}$ channels subunits *Kcnj11* and *Abcc8*, and *Snap25*, which mediate the calcium signaling necessary for insulin secretion ([Tables 1](#t1){ref-type="table"}, [4](#t4){ref-type="table"}, and [5](#t5){ref-type="table"}), or in cytosolic ${Ca}^{2 +}$ levels in isolated islets of F1 and F2 LowerB and UpperB adult males relative to Controls (see Figure S5). These results demonstrate that the effects of BPA exposure are mediated preferentially by *Esr1* and not *Esr2* or targets of *Esr2* in our study.

###### 

Genes with $q < 0.1$ in F1 Lower BPA male vs. Control male from RNA seq analysis. The genes that were assessed via qPCR are included in the table (rows 10--20) for completeness.

Table 4 lists serial numbers in the first column; the corresponding gene names, log FC values, logCPM values, p-values, and q-value.BH are listed in the other columns.

  Serial no.   Gene name   logFC       logCPM     *p*-Value   QValue.BH
  ------------ ----------- ----------- ---------- ----------- -----------
  1            *Lars2*     $- 2.68$    9.43       1.49E-06    0.04
  2            *Cth*       $- 2.81$    2.43       1.60E-06    0.04
  3            *Klk1b22*   $- 12.35$   $- 0.04$   8.85E-06    0.08
  4            *Cyp2c70*   $- 3.67$    $- 2.71$   1.32E-05    0.08
  5            *Cpa5*      $- 10.75$   5.70       1.41E-05    0.08
  6            *Klk1b24*   $- 5.32$    1.56       1.65E-05    0.08
  7            *Tinag*     $- 2.48$    1.01       2.22E-05    0.09
  8            *Reg3a*     $- 4.02$    3.38       2.83E-05    0.09
  9            *Fgf21*     $- 3.78$    0.34       2.88E-05    0.09
  10           *Igf2*      4.27        1.26       0.02        0.80
  11           *Esr1*      $- 2.77$    1.56       0.18        0.80
  12           *Esr2*      $- 2.76$    0.87       0.18        0.80
  13           *Snap25*    $- 1.63$    1.58       0.31        0.98
  14           *Kcnj11*    $- 0.60$    6.35       0.31        0.98
  15           *Ogdh*      0.31        2.77       0.70        1.00
  16           *Abcc8*     0.18        5.18       0.77        1.00
  17           *Pdx1*      0.25        2.62       0.78        1.00
  18           *Igf1*      0.18        2.41       0.83        1.00
  19           *Ucp2*      $- 0.34$    1.15       0.84        1.00
  20           *Hnf1a*     $- 0.09$    6.06       0.86        1.00

Note: CPM, counts per million; FC, fold change. $n = 3$ litters per group (islets pooled from 2--3 male mice per litter).

###### 

Genes with $q < 0.1$ in F1 Upper BPA male vs. Control male from RNA seq analysis. The genes that were assessed via qPCR are included in the table (rows 42--52) for completeness.

Table 5 lists serial numbers in the first column; the corresponding gene names, log FC values, logCPM values, p-values, and q-value.BH are listed in the other columns.

  Serial no.   Gene name         logFC      logCPM   *p*-Value   QValue.BH
  ------------ ----------------- ---------- -------- ----------- -----------
  1            *Lars2*           $- 4.65$   9.43     1.99E-14    4.87E-10
  2            *Rn45s*           $- 2.84$   13.57    7.84E-10    9.59E-06
  3            *Dbt*             $- 3.60$   3.19     3.93E-07    0.003
  4            *Klk1b5*          $- 4.64$   2.25     5.21E-06    0.03
  5            *Matn4*           $- 1.92$   9.06     7.90E-06    0.004
  6            *Ctnnbip1*        $- 1.83$   6.67     1.75E-05    0.007
  7            *Sdhc*            $- 2.06$   4.94     6.00E-05    0.02
  8            *Spryd4*          $- 2.34$   4.13     6.11E-05    0.02
  9            *Chst2*           $- 2.15$   5.92     8.48E-05    0.02
  10           *Nccrp1*          $- 2.27$   4.16     0.0002      0.03
  11           *2610203C22Rik*   $- 1.83$   4.51     0.0003      0.04
  12           *Gm5148*          $- 1.53$   10.35    0.0002      0.04
  13           *Zfhx2os*         1.45       6.56     0.0003      0.05
  14           *Fam69a*          $- 1.54$   8.97     0.0003      0.05
  15           *0610039K10Rik*   $- 1.37$   9.10     0.0006      0.06
  16           *9530027J09Rik*   $- 0.87$   7.67     0.0008      0.06
  17           *Casc1*           $- 1.79$   4.96     0.0005      0.06
  18           *Ccdc176*         $- 1.48$   7.85     0.0007      0.06
  19           *Ifi27l2a*        $- 1.51$   4.68     0.0006      0.06
  20           *Loxl3*           $- 1.16$   7.96     0.0007      0.06
  21           *Lrrc75b*         $- 1.77$   4.31     0.0007      0.06
  22           *Pigf*            $- 0.86$   8.57     0.0007      0.06
  23           *4930429F24Rik*   1.29       5.68     0.0009      0.06
  24           *Nphs1os*         $- 1.72$   7.69     0.0009      0.06
  25           *1700028J19Rik*   $- 1.70$   4.77     0.001       0.07
  26           *A230070E04Rik*   1.45       5.51     0.001       0.07
  27           *Adam17*          $- 1.30$   7.30     0.002       0.08
  28           *Arhgap26*        $- 1.57$   4.72     0.002       0.08
  29           *C330022C24Rik*   $- 1.67$   5.73     0.002       0.08
  30           *Cand2*           $- 1.52$   11.15    0.001       0.08
  31           *Casp9*           $- 2.02$   18.49    0.002       0.08
  32           *Snx22*           $- 1.57$   12.90    0.002       0.08
  33           *Spg11*           $- 0.89$   6.16     0.001       0.08
  34           *Tap2*            $- 1.68$   5.53     0.002       0.08
  35           *Vmn2r9*          $- 1.62$   6.12     0.002       0.08
  36           *Gm5088*          $- 1.55$   10.41    0.002       0.08
  37           *Gtf2i*           $- 2.10$   4.38     0.002       0.08
  38           *Txnip*           $- 1.25$   5.21     0.002       0.08
  39           *Prss57*          $- 0.92$   6.75     0.002       0.09
  40           *Tspan4*          $- 0.88$   6.53     0.002       0.09
  41           *Slc12a4*         $- 1.78$   4.98     0.002       0.09
  42           *Esr1*            1.62       1.56     0.20        0.94
  43           *Abcc8*           0.78       5.18     0.19        0.94
  44           *Igf2*            1.24       1.26     0.28        0.94
  45           *Esr2*            $- 1.50$   0.87     0.35        0.94
  46           *Pdx1*            0.67       2.62     0.39        0.97
  47           *Igf1*            $- 0.47$   2.41     0.56        1
  48           *Hnf1a*           $- 0.19$   6.06     0.71        1
  49           *Snap25*          0.34       1.58     0.76        1
  50           *Ogdh*            0.16       2.77     0.83        1
  51           *Kcnj11*          0.07       6.35     0.90        1
  52           *Ucp2*            0.07       1.15     0.97        1

Note: CPM, counts per million; FC, fold change. $n = 3$ litters per group (islets pooled from 2--3 male mice per litter).

To determine whether BPA mediates change in islets *Esr1* gene expression via DNA methylation as shown by others in mouse ([@c50]) and rat ([@c19]) brain, we assessed methylation status of 16 CpG sites across untranslated exon A and exon C of *Esr1* gene in islets. We observed similar percent methylation at all five CpG sites of exon C among the three groups (see Figure S6). We observed minimal (4--5%), yet dose-specific, changes in the DNA methylation levels of exon A in islets ([Figure 8](#f8){ref-type="fig"}). F1 LowerB males trended toward increased methylation levels at CpG sites 1 and 4, but F2 LowerB males had similar percent methylation level at all CpG sites examined relative to Controls ([Figure 8](#f8){ref-type="fig"}). The mean methylation across all CpG sites was also similar in F1 and F2 LowerB males compared with Controls. In contrast, F2 UpperB males trend toward increased methylation at CpG sites 3, 4, 5, and 10 and mean methylation across all CpG sites relative to Controls ([Figure 8](#f8){ref-type="fig"}). F1 UpperB males had similar methylation at individual CpG sites and mean methylation across all CpG sites relative to Controls ([Figure 8](#f8){ref-type="fig"}). On repeated measures analysis, we observed significant differences in methylation levels between CpG sites ($p < 0.01$); however, we saw no statistical difference in methylation levels between the groups ($p > 0.1$) or groups\*CpG site interaction ($p > 0.1$) in islets of F1 and F2 males. Overall these findings indicate that BPA had minimal effects on *Esr1* methylation in islets. It is possible that in addition to these minimal differences in methylation levels, BPA may be mediating its effect on *Esr1* via other regulatory mechanisms such as changes in chromatin acetylation/methylation levels. This requires further investigation.

![Percent DNA methylation at Igf2 DMR1 and Esr1 Exon A in islets of F1 and F2 adult male offspring: (*A--B*) F1 and (*C--D*) F2 adult male offspring. Data are percent CpG methylation values from individual litter (islets pooled from 2--3 males from the same litter) and presented as $\text{mean} + \text{SEM}$. Data were analyzed using Dunnett's test; *p*-Values are relative to Control. \*\* $p < 0.05$, \* $p > 0.05$ and $p < 0.09$.](EHP1674_f8){#f8}

Effects of Maternal BPA Exposure on Igf2 Expression and DNA Methylation at Igf2 DMR1 in Islets of F1 and F2 Adult Male Offspring {#s3.5}
--------------------------------------------------------------------------------------------------------------------------------

Insulin-like growth factor 2 (*Igf2*) plays a critical role in $\beta - \text{cell}$ function, proliferation, and apoptosis. We and others have reported that *Igf2* overexpression is associated with impaired glucose tolerance ([@c34]; [@c92]) and impaired insulin secretion ([@c34]; [@c70]). Overexpression of *Igf2* has also been reported to lead to $\beta - \text{cell}$ dysfunction and marked morphological abnormalities of the islet ([@c17]). In previous studies, we observed an increased expression of *Igf2* in F1 and F2 upper dose BPA-exposed embryos ([@c91]). Thus, to determine whether *Igf2* expression is also increased postnatally in islets and whether these changes persist into the next generation, we measured mRNA levels in islets from F1 and F2 LowerB and UpperB groups by quantitative PCR (qPCR). We found that *Igf2* mRNA levels were significantly increased in F1 and F2 LowerB and UpperB males compared with Controls ([Table 1](#t1){ref-type="table"}).

Previously, we determined that the increase in expression of *Igf2* in F1 and F2 islets in UpperB males was associated with increased methylation at the *Igf2* DMR1 ([@c91], [@c92]). Thus, we measured DNA methylation at *H19/Igf2* imprinting control region (ICR) and at *Igf2* DMR1 in islets. F1 and F2 LowerB males had DNA methylation levels at *Igf2* DMR1 and *H19/Igf2* ICR comparable with Controls ([Figure 8](#f8){ref-type="fig"}; see also Figure S6). In contrast, F1 UpperB males had increased methylation at CpG site 1 and increased mean methylation, and F2 UpperB males had increased methylation at CpG sites 1 and 2 as well as increased mean methylation at *Igf2* DMR1 relative to Controls ([Figure 8](#f8){ref-type="fig"}). Interestingly, on repeated measures, we observed differences in methylation levels across CpG sites (F1 $p < 0.01$; F2 $p < 0.01$) and between groups (F1 $p = 0.04$; F2 $p = 0.02$), but no statistical difference in groups\*CpG site interaction (F1 $p > 0.1$; F2 $p > 0.1$) at *Igf2* DMR1. This analysis indicated that BPA affects methylation level at CpG sites but does not account for the methylation differences between CpG sites at *Igf2* DMR1. However, we saw no difference in methylation at *H19/Igf2* ICR (see Figure S6), suggesting that the increase in *Igf2* expression in the islet results from increased expression of the normally expressed paternal allele and not loss of imprinting.

Effects of Maternal BPA Exposure on the Transcriptome of F1 Adult Male and Female Offspring {#s3.6}
-------------------------------------------------------------------------------------------

To identify novel pathways and to determine whether changes in islet phenotypes in BPA-exposed mice are regulated at the gene expression level, we conducted whole transcriptome analysis via RNA sequencing in males and females. Consistent with our phenotypic data, we saw no differentially expressed genes in females ([Tables 6](#t6){ref-type="table"} and [7](#t7){ref-type="table"}). Because of interanimal variability and the small sample size, there were very few differentially expressed genes in males when the analysis was corrected for multiple testing ($q < 0.05$). Interestingly, however, of the few differentially expressed genes, there was minimal overlap between the LowerB and UpperB males ([Figure 9](#f9){ref-type="fig"}), consistent with the observed dose-specific phenotypes. Moreover, qPCR of several key islet genes demonstrated robust differences between the groups despite higher *q*-values in the RNAseq analysis ([Tables 1](#t1){ref-type="table"}, [4](#t4){ref-type="table"}, [5](#t5){ref-type="table"}). Thus, we performed ingenuity pathway analysis on the RNAseq data using a $p < 0.05$ and a fold change of 1.5. Multiple genes associated with inflammation in LowerB males, and both inflammation and mitochondrial function including branched-chain $\alpha - \text{keto}$ acid dehydrogenase complex in UpperB males were altered compared with Controls, which is consistent with the phenotypic data ([Figure 9](#f9){ref-type="fig"}). Other pathways that are critical for normal pancreatic development and regulation of insulin secretion such as sonic hedgehog ([@c95]) and gap-junction signaling ([@c12]; [@c48]) were altered in LowerB males, whereas pathways involved in inflammation and mitochondrial dysfunction such as G-protein couple receptor ([@c69]; [@c88]) and endoplasmic reticulum stress ([@c74]) and signaling were altered in UpperB males. Unexpectedly, there were minimal changes in mRNA expression levels as determined by RNA Seq and qPCR of other $\beta - \text{cell}$ regulatory genes such as *Pdx1*, *Igf1*, and *Hnf1a* in BPA groups compared with Controls ([Tables 1](#t1){ref-type="table"}, [4](#t4){ref-type="table"}, and [5](#t5){ref-type="table"}).

![RNA Seq data in islets of F1 male mice. (*A*) F1 Lower BPA male vs. Control male canonical pathways from Ingenuity Pathway Analysis (IPA); IPA parameters: 962 genes; $p < 0.05$; inflammatory pathways highlighted by the rectangular box. (*B*) F1 Upper BPA male vs. Control male canonical Pathways from IPA; IPA parameters: 1,275 genes; $p < 0.05$; inflammatory and mitochondrial dysfunction pathways highlighted by the rectangular box. (*C*) Venn diagram illustrating number of differentially expressed genes when comparing F1 Lower BPA (LowerB), Upper BPA (UpperB), and Control males; parameters: false discovery rate (FDR) $< 10\%$, which is equivalent to $p$ adjusted (also known as *q*-value) $< 0.1$; $n = 3$ litters (islets pooled from 2--3 males from the same litter) per group.](EHP1674_f9){#f9}

###### 

Top 25 genes, by *p*-values, in F1 Lower BPA female vs. Control female from RNA seq analysis.

Table 6 lists serial numbers in the first column; the corresponding gene names, log FC values, logCPM values, p-values, and q-value.BH are listed in the other columns.

  Serial no.   Gene name         logFC      logCPM   *p*-Value   QValue.BH
  ------------ ----------------- ---------- -------- ----------- -----------
  1            *Creb3l3*         $- 5.83$   2.61     9.51E-05    1
  2            *4833419F23Rik*   5.26       2.44     2.03E-04    1
  3            *Gm10012*         $- 6.86$   2.66     3.88E-04    1
  4            *Mpzl2*           5.01       1.96     3.88E-04    1
  5            *Fam204a*         5.13       2.23     7.35E-04    1
  6            *Krt19*           $- 5.48$   2.51     7.40E-04    1
  7            *Nedd9*           $- 5.07$   2.14     7.86E-04    1
  8            *4930470O06Rik*   $- 5.65$   2.03     8.05E-04    1
  9            *Egr1*            $- 4.95$   2.23     9.15E-04    1
  10           *1700019G17Rik*   $- 5.28$   2.32     0.001       1
  11           *Trmt5*           4.89       2.24     0.001       1
  12           *Espl1*           $- 5.20$   2.04     0.001       1
  13           *St18*            $- 5.18$   2.65     0.001       1
  14           *Tspan2os*        $- 4.07$   2.74     0.001       1
  15           *Drg1*            $- 4.89$   2.25     0.001       1
  16           *Ggta1*           5.51       2.06     0.001       1
  17           *Fbxw7*           $- 4.84$   2.28     0.001       1
  18           *Serf2*           $- 4.85$   2.29     0.001       1
  19           *4930509J09Rik*   $- 5.05$   2.40     0.001       1
  20           *Dhrs1*           $- 5.02$   2.21     0.001       1
  21           *8430437L04Rik*   $- 5.29$   1.96     0.001       1
  22           *Rragb*           4.71       2.38     0.002       1
  23           *Sh3bgr*          4.66       1.80     0.002       1
  24           *Taf11*           $- 4.86$   2.12     0.002       1
  25           *4931431B13Rik*   $- 5.67$   4.75     0.002       1

Note: CPM, counts per million; FC, fold change. $n = 3$ litters per group (islets pooled from 2--3 female mice per litter).

###### 

Top 25 genes, by *p*-values, in F1 Upper BPA female vs. Control female from RNA seq analysis.

Table 7 lists serial number in the first column; the corresponding gene names, log FC values, logCPM values, p-values, and q-value.BH are listed in the other columns.

  Serial no.   Gene name         logFC      logCPM   *p*-Value   QValue.BH
  ------------ ----------------- ---------- -------- ----------- -----------
  1            *Fabp1*           $- 9.26$   5.54     4.93E-05    0.83
  2            *Spr*             5.41       2.14     8.67E-05    0.83
  3            *Gda*             $- 6.75$   3.71     1.82E-04    0.83
  4            *BC051537*        3.19       5.86     2.27E-04    0.83
  5            *St3gal4*         $- 5.99$   3.01     2.86E-04    0.83
  6            *Rragb*           5.26       2.38     3.79E-04    0.83
  7            *Wdr74*           4.98       2.01     4.44E-04    0.83
  8            *Myo1a*           $- 7.73$   4.63     4.77E-04    0.83
  9            *Rprm*            5.64       2.26     5.47E-04    0.83
  10           *Pcsk5*           $- 5.61$   2.50     0.0006      0.83
  11           *Psmg3*           $- 5.78$   3.18     0.0006      0.83
  12           *Smim24*          $- 4.89$   5.48     0.0007      0.83
  13           *Apoa1*           $- 6.47$   5.39     0.0007      0.83
  14           *Rab40b*          5.35       2.17     0.0007      0.83
  15           *Rbp2*            $- 6.40$   4.70     0.0008      0.83
  16           *Ephx2*           $- 6.12$   3.12     0.0009      0.83
  17           *Ccs*             $- 5.09$   2.77     0.0009      0.83
  18           *Ano3*            $- 5.57$   2.56     0.0009      0.83
  19           *Tctn1*           2.22       8.44     0.0009      0.83
  20           *4833419F23Rik*   4.78       2.44     0.001       0.83
  21           *Adipor2*         $- 3.01$   3.21     0.001       0.83
  22           *Enpp3*           $- 5.20$   2.33     0.001       0.83
  23           *Slc15a1*         $- 6.30$   3.33     0.001       0.83
  24           *Pkdrej*          $- 3.77$   2.69     0.001       0.83
  25           *Sis*             $- 5.91$   6.32     0.001       0.83

Note: CPM, counts per million; FC, fold change. $n = 3$ litters per group (islets pooled from 2--3 female mice per litter).

Discussion {#s4}
==========

We recently reported that early-life exposure to the endocrine-disrupting chemical BPA in the mouse is associated with sex-specific metabolic health defects across multiple generations ([@c92]). In the current study, we provide further evidence that BPA has sex-specific effects, such that the islet function of only males is affected. Additionally, we observed dose-specific effects in male offspring of dams fed a lower-dose versus a higher-dose BPA diet. We show here that the insulin secretory defect in male offspring is associated with impaired mitochondrial function in UpperB mice and reduced $\beta - \text{cell}$ mass in the LowerB mice ([Table 8](#t8){ref-type="table"}). It is not uncommon to find dose-specific effects following exposure to endocrine-disrupting chemicals ([@c99]). Various studies in the mouse have shown that BPA affects metabolism ([@c6]), DNA methylation levels ([@c44]), and behavior ([@c41]) in a dose-specific manner. The dose-specific findings of the current study are consistent with these previous studies. Uniquely, our current study shows that the dose-specific effects of BPA on the pancreas are not limited to the first, but are transmitted to the second generation. These persistent phenotypic changes into at least the second generation are not due to an altered metabolic milieu in the pregnant F1 female, and thus may be transmitted through epigenetic mechanisms or via mitochondria ([@c92]). Our current findings of persistent changes in DNA methylation at *Igf2* and altered mitochondria function in $\beta\,\text{cells}$ in F1 and F2 offspring suggest that both mechanisms are involved.

###### 

Dose-specific effects of bisphenol A on pancreatic islets of male offspring.

Table 8 lists Lower BPA and Upper BPA for the F1 and F2 generation in the first column. The significance of insulin content and cytosolic/calcium is listed in the second and third columns, respectively. The KIC ramp, Oroboros, and mRNA or protein levels for mitochondria; histology and viability assay for beta cell mass and Islet viability; mRNA or protein levels, Igf2/Esr1 methylation for gene expression and methylation; and Luminex, ELISA, and histology for inflammation are listed in the other columns

  Group           Insulin content                     Cytosolic calcium  Mitochondria                                  Beta cell mass, and islet viability          Gene expression and methylation                                       Inflammation                                                                                                                                                                                                                                                                                                               
  --------------- ---------------------------------- ------------------- --------------------------------------------- -------------------------------------------- --------------------------------------------------------------------- ---------------------------------------- ------------------------------------------ ----------------------------------------------------------- -------------------------------------- -------------------------------------------------------------------------------------------- -------------------------------------- --------------------------------------
  F1 GENERATION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
   LowerB         $\downarrow$ insulin content^\#^           NS          NS                                            NS                                           $\uparrow$*Ucp2*$\uparrow$ UCP2 protein levels NS                     $\downarrow$$\beta - \text{cell}$ mass   $\uparrow$ Cell death                      $\uparrow$*Igf2*, $\downarrow$*Esr1*$\downarrow$ ESR1^\#^   $\uparrow$*Esr1*^\#^                   $\uparrow$ IL5^\#^                                                                           $\uparrow$ IL6^\#^$\uparrow$ MCP1 NS   $\uparrow$ CD3, $\uparrow$ F4/80
   UpperB         NS                                         NS          $\downarrow$ KIC-stimulated insulin release   $\downarrow$ Basal and maximal respiration   $\uparrow$*Ucp2*$\uparrow$ UCP2 protein levels NS                     NS                                       $\uparrow$ Akt-phos, $\uparrow$ Bcl2^\#^   $\uparrow$*Igf2*, $\downarrow$*Esr1* ESR1 NS                $\uparrow$*Igf2*                       $\uparrow$ IL5, $\uparrow$ IL6^\#^, $\uparrow$ MCP1, $\uparrow$ G-CSF, $\uparrow$ IL9^\#^    $\uparrow$ IL6, NS $\uparrow$ MCP1     $\uparrow$ CD3, $\uparrow$ F4/80
  F2 GENERATION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
   LowerB         $\downarrow$ insulin content^\#^           NS          NS                                            NS                                           $\uparrow$*Ucp2*, $\uparrow$*Ogdh*$\uparrow$ UCP2 protein levels NS   $\downarrow$$\beta - \text{cell}$ mass   $\uparrow$ Cell death^\#^                  $\uparrow$*Igf2*, $\downarrow$*Esr1*$\downarrow$ ESR1^\#^   NS                                     $\uparrow$ IL17                                                                              $\uparrow$ IL6^\#^$\uparrow$ MCP1      $\uparrow$ CD3, $\uparrow$ F4/80^\#^
   UpperB         NS                                         NS          $\downarrow$ KIC-stimulated insulin release   $\downarrow$ Basal and maximal respiration   $\uparrow$*Ucp2*$\uparrow$ UCP2 protein levels NS                     NS                                       $\uparrow$ Akt-phos                        $\uparrow$*Igf2*, $\downarrow$*Esr1* ESR1 NS                $\uparrow$*Igf2*$\uparrow$*Esr1*^\#^   $\downarrow$ IL4, $\uparrow$ IL5^\#^, $\uparrow$ IL6, $\uparrow$ IL17, $\uparrow$ MCP1^\#^   $\uparrow$ IL6, NS $\uparrow$ MCP1     $\uparrow$ CD3, $\uparrow$ F4/80

Note: Arrows indicate levels are statistically ($p < 0.05$) increased or decreased relative to Controls. LowerB, Lower BPA ($10\;\mu g/{kg}/d$); NS, not significant ($p > 0.1$); UpperB, Upper BPA ($10\;{mg}/{kg}/d$). ^\#^$p < 0.05$ and $p < 0.1$~.~

Mitochondrial impairment, and altered expression levels of key mitochondrial genes such as *Ucp2* and *Ogdh* have been previously reported in the pancreas of first-generation adult male offspring of BPA-exposed rat dams ([@c101]), in isolated rat islets ([@c85]), and in BPA-exposed INS1 cells ([@c57]). Importantly, others have shown that increased *Ucp2* expression increases efflux of acetyl-CoA--oxidizing substrates such as $\alpha - \text{ketoglutarate}$ of the TCA cycle out of the mitochondria ([@c100]). It is known that $\alpha - \text{ketoisocaproate}$ promotes glutamate oxidation to produce $\alpha - \text{ketoglutarate}$ ([@c111]). Therefore, the increased *Ucp2* expression with an efflux of TCA intermediates from the mitochondria as previously shown ([@c100]) suggests altered $\alpha - \text{ketoisocaproate}$ metabolism. Although in the current study we observed increased *Ucp2* mRNA expression levels in BPA-exposed groups, we did not find statistically increased UCP2 protein levels. However, our transcriptome analysis revealed differential expression of other genes such as *Ucp2* that are also involved in the branched-chain $\alpha - \text{ketoacid}$ dehydrogenase complex, which catalyzes the metabolism of branched-chain amino acids such as leucine and its derivative, $\alpha - \text{ketoisocaproate}$. This is consistent with a reduction in $\alpha - \text{ketoisocaproate}$--stimulated insulin secretion in the UpperB group. Therefore, it may be that genes other than *Ucp2* impair $\alpha - \text{ketoisocaproate}$ metabolism, consequently affecting $\alpha - \text{ketoisocaproate}$--stimulated insulin secretion.

Reduced $\alpha - \text{ketoisocaproate}$--stimulated insulin secretion and mitochondrial dysfunction persisting until the second generation in islets of the UpperB group indicate that the higher dose of BPA is associated with mitochondrial impairment. Mitochondrial impairment is associated with the production of reactive oxygen species (ROS) such as superoxide, hydrogen peroxide, and hydroxyl radicals as seen in different type 2 diabetes models and IUGR rats ([@c13]; [@c36]; [@c82]). ROS can lead to the activation of $\text{NF} - \kappa B$, which in turn increases pro-inflammatory cytokine production ([@c43]), eventually leading to increased $\beta - \text{cell}$ death and dysfunction. Our study demonstrates that UpperB exposure is associated with impaired mitochondrial function and increased pro-inflammatory cytokine production. Whether this is due to oxidative stress remains to be determined. Elevated pro-inflammatory cytokine levels have been shown to induce $\beta - \text{cell}$ death ([@c77]), which in turn reduces $\beta - \text{cell}$ mass. AKT phosphorylation inhibits programed cell death ([@c72]; [@c103]); in the current study, increased AKT phosphorylation levels and the lack of changes in cell death observed in UpperB islets are consistent with these previous findings. The mechanism underlying this change remains to be determined.

Despite the lack of changes in mitochondrial function in the LowerB group, the first- and second-generation offspring of this group had significantly reduced $\beta - \text{cell}$ function as defined by impaired insulin secretion, which suggested that a lower dose of BPA may act via an alternate pathway in $\beta\,\text{cells}$, such as a reduction in $\beta - \text{cell}$ mass. Impaired insulin secretion is known to be secondary to reduced $\beta - \text{cell}$ mass in humans ([@c16]; [@c71]; [@c104]) and animals ([@c10]; [@c47]; [@c65]; [@c83]). Indeed, we observed reduced $\beta - \text{cell}$ mass adjusted for body weight across two generations in adult male offspring of LowerB exposed dams, and these changes were associated with increased cell death. These finding are consistent with previous studies that reported reduced $\beta - \text{cell}$ mass at birth in the offspring of rats exposed to $10\;\mu g$ BPA/kg body weight per day throughout gestation and lactation ([@c20]) and increased cell death in BPA-exposed INS1 cells ([@c30]; [@c57]). $\beta - \text{cell}$ mass was also reduced and cell death was increased at 6 mo after delivery in female mice that were exposed to BPA during pregnancy ([@c3]). Interestingly, when C57BL/6 mice dams were subcutaneously injected from either day 6 of pregnancy (P6) until birth (PND0), PND0 until weaning (PND21), or P6-PND21 with $100\;\mu g$ BPA/kg body weight per day, $\beta - \text{cell}$ mass was increased in 3-mo-old male offspring ([@c58]). Differences in timing, dose, route of exposure, and methods of measurement of $\beta - \text{cell}$ mass that were not corrected for body weight may explain the different results in our study compared with those of Liu et al. ([@c58]). In rodents, ($\beta - \text{cell}$ mass has a linear correlation with body weight such that $\beta - \text{cell}$ mass increases with body weight ([@c64]). Therefore, we corrected $\beta - \text{cell}$ mass for body weight in our study, so that any changes due to difference in body weight *per se* would be accounted for. We chose oral BPA exposure via diet as it has been shown to be effective and a representative model of human exposures because humans are chronically exposed to BPA primarily through ingestion, and our doses are well within the human exposure limits ([@c91]; [@c81]). Importantly, end points measured in this study were from animals generated across multiple cohorts studied in two different animal care facilities with a control group included in each cohort. This reflects robustness of the studied outcomes and cohort consistency in our paradigm.

Our study is the first to show that developmental BPA exposure induces inflammation in the islet in both F1 and F2 generations. Although immune cells are present in the pancreas and play an important role in normal pancreatic development ([@c23]; [@c29]; [@c39], [@c38]), several studies have reported that increased cytokine levels, and increased immune cell infiltration in islets, is associated with $\beta - \text{cell}$ dysfunction in type 2 diabetes ([@c14]; [@c25]; [@c33]; [@c45]; [@c56]; [@c60]; [@c73]). Increased levels of pro-inflammatory cytokines such as IL6 and MCP1 reduce insulin secretion in human and mouse islets ([@c77]). Inflammatory cytokines also impair mitochondria function in the $\beta\,\text{cell}$, which in turn blunts insulin secretion ([@c28]). Thus, it is likely that BPA-induced islet inflammation plays a key role in the abnormal $\beta - \text{cell}$ phenotype observed in F1 and F2 mice.

BPA is an estrogen mimic, and therefore, it is plausible that BPA could alter *Esr1* expression. In fact, maternal BPA exposure has been shown to down-regulate *Esr1* mRNA and protein expression at P7 and P21 in the hippocampus of male rat offspring ([@c102]). Two injections of ICI 182,780, a brain-permeable endoplasmic reticulum (ER) antagonist, in rat pups were able to reverse this change, demonstrating that BPA is causal in reducing *Esr1* expression ([@c102]). Consistent with these findings, we observed reduced *Esr1* gene expression in islets of both BPA exposure groups, and reduced ESR1 protein levels in lower-dose exposure group. However, because BPA has weak binding affinity for estrogen receptors relative to estrogens, it is likely that BPA mediates its effect on estrogen receptor expression without directly binding to the receptor. Other mechanisms, such as a direct effect on DNA methylation, may instead be responsible for altering *Esr1* gene expression as shown in the mouse ([@c50]) and rat brain ([@c19]). We assessed DNA methylation status at 16 CpG sites in exon A and exon C of *Esr1* gene in islets, and found minimal differences. It is possible that other gene regulatory mechanisms such as a change in chromatin conformation may be involved. This remains to be determined.

Estrogen receptors are widely distributed in the thymus ([@c42]), bone marrow ([@c84]), and spleen ([@c76]), suggesting that they play a role in regulating normal immune response. In fact, loss of *Esr1* leads to perturbed development of the thymus and spleen ([@c26]) and to altered immune responses ([@c24]; [@c51]; [@c61]). Altered *Esr1* expression could therefore influence the effect of developmental exposure to BPA on the pancreatic immune response, leading to the increased inflammation that we observed in the islets of the BPA-exposed animals in this study.

It is remarkable that the changes we reported in *Igf2* expression and DNA methylation in the embryo persist in the islet in adulthood and into the next generation. Further, in previous studies, the metabolic phenotypes in the F1 and F2 BPA male offspring were linked to *Igf2* overexpression ([@c92]). Although *Igf2* is protective in the adult $\beta\,\text{cell}$ and increased expression prevents $\beta - \text{cell}$ death ([@c22]; [@c35]), overexpression of *Igf2* in the fetus results in marked $\beta - \text{cell}$ abnormalities in fetal and adult life ([@c17]; [@c34]; [@c70]). These $\beta - \text{cell}$ abnormalities may be secondary to increased islet inflammation because *Igf2* overexpression has been reported to be associated with increased immune cell infiltration in the rodent pancreas ([@c17]). Therefore, it is plausible to suggest that *Igf2* in combination with reduced *Esr1* mediates the increased inflammatory response that we observed in islets of the BPA-exposed animals.

Finally, ingenuity pathway analysis of the RNAseq data revealed multiple pathways that were altered and could contribute to the abnormal pancreatic phenotype in the offspring of BPA-exposed mice, including sonic hedgehog (Shh) and gap-junction signaling in the LowerB dose group and ER stress in the UpperB dose group. Shh is known to play a critical role in pancreatic development ([@c95]), and gap junctions help establish cross-talk within islet cells thereby regulating normal insulin secretion and $\beta - \text{cell}$ mass ([@c12]; [@c48]). ER stress is associated with mitochondrial dysfunction ([@c74]). Although we did not further interrogate these pathways in our study, they remain important targets for future research.

Conclusion {#s5}
==========

The current study elucidates the underlying mechanisms responsible for impaired insulin secretion in mice exposed to relevant human exposure levels of BPA during development. The persistent changes in insulin secretion, mitochondria function, and $\beta - \text{cell}$ mass across multiple generations are consistent with an epigenetically mediated mechanism. These findings have public health ramifications and identify $\beta - \text{cell}–\text{specific}$ targets of BPA that could be used to develop potential therapeutic strategies to prevent environment-induced diabetes.
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